Comparison of paclitaxel-cetuximab chemotherapy versus metronomic chemotherapy consisting of methotrexate and celecoxib as palliative chemotherapy in head and neck cancers.
In Indian Journal of Cancer.
By: Patil VM.
Contributor(s): Noronha V | Joshi A | Agarwala V | Muddu V | Ramaswamy A | Chandrasekharan A | Dhumal S | Juvekar S | Arya A | Bhattacharjee A | Prabhash K [Corresponding author].
Material type:
ArticlePublisher: 2017Description: .Subject(s): Chemotherapy | Head and Neck Cancer | Metronomic | Metronomic administration | Metronomic dosing | Palliative
In:
Indian Journal of CancerSummary: Abstract
BACKGROUND:
The present match pair analysis was planned to compare the efficacy of cetuximab-paclitaxel-based chemotherapy versus metronomic therapy.
MATERIALS AND METHODS:
Sixty patients with metastatic/recurrent head and neck squamous cell cancer treated with weekly paclitaxel (80 mg/m2) and cetuximab were matched with sixty patients treated with oral metronomic chemotherapy consisting of methotrexate and celecoxib. The progression-free survival (PFS) and overall survival (OS) between the cohorts were compared using log-rank test. Cox proportional regression model was used to identify independent factors affecting PFS and OS.
RESULTS:
The median OS was 191 days (95% confidence interval [CI]: 122.2-259.8 days) in metronomic cohort and 256 days (95% CI 177.0-334.9 days) in cetuximab cohort (hazard ratio: 0.58, 95% CI: 0.35-0.95, P = 0.031). On Cox proportional hazard model, Eastern Cooperative Oncology Group Performance Status (0-1 vs. 2) and therapy (cetuximab versus metronomic) had a statistically significant impact on OS.
CONCLUSION:
Cetuximab-based chemotherapy leads to a significant improvement in OS in the match pair analysis in comparison to metronomic chemotherapy.
| Item type | Current location | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|
Articles
|
Tata Memorial Hospital | Available | AR18695 |
Address for correspondence: kumarprabhashtmh@gmail.com
Abstract
BACKGROUND:
The present match pair analysis was planned to compare the efficacy of cetuximab-paclitaxel-based chemotherapy versus metronomic therapy.
MATERIALS AND METHODS:
Sixty patients with metastatic/recurrent head and neck squamous cell cancer treated with weekly paclitaxel (80 mg/m2) and cetuximab were matched with sixty patients treated with oral metronomic chemotherapy consisting of methotrexate and celecoxib. The progression-free survival (PFS) and overall survival (OS) between the cohorts were compared using log-rank test. Cox proportional regression model was used to identify independent factors affecting PFS and OS.
RESULTS:
The median OS was 191 days (95% confidence interval [CI]: 122.2-259.8 days) in metronomic cohort and 256 days (95% CI 177.0-334.9 days) in cetuximab cohort (hazard ratio: 0.58, 95% CI: 0.35-0.95, P = 0.031). On Cox proportional hazard model, Eastern Cooperative Oncology Group Performance Status (0-1 vs. 2) and therapy (cetuximab versus metronomic) had a statistically significant impact on OS.
CONCLUSION:
Cetuximab-based chemotherapy leads to a significant improvement in OS in the match pair analysis in comparison to metronomic chemotherapy.
There are no comments for this item.